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Three hundred and fifty-three asthmatic patients who remained symptomatic despite treatment with budesonide
800–1200 mg day71 (or equivalent) were randomized to a new combination therapy comprising salmeterol 50 mg and
fluticasone propionate 250mg (SeretideTM, AdvairTM, VianiTM 50/250mg) twice daily or budesonide 800mg twice
daily for 24 weeks. Patients kept daily records of their morning and evening peak expiratory flow (PEF), daytime
and night-time symptom scores and daytime and night-time use of rescue salbutamol.
Mean morning PEF increased by 45 lmin71 (baseline 361 lmin71) in the salmeterol/fluticasone propionate
combination (SFC) group and by 19 lmin71 (baseline 358 lmin71) in the budesonide group over the 24 weeks. The
adjusted mean morning PEF over weeks 1 to 24 was significantly greater in the SFC group, despite the4 three-fold
lower corticosteroid dose (406 vs. 380 lmin71; P50?001). A significantly greater improvement in evening PEF was
also seen in the SFC group (adjusted mean 416 vs. 398 lmin71; P50?001). SFC also provided significantly better
control of daytime symptoms and a significantly greater reduction in the requirement for rescue salbutamol
compared with budesonide.
These results demonstrate that SFC 50/250mg twice daily is superior to budesonide 800 mg twice daily in the
management of patients with moderate to severe asthma who are symptomatic on their existing dose of
corticosteroid.
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Inhaled corticosteroids are the most eective anti-inflam-
matory agents for the treatment of asthma, producing
improvements in lung function and symptom control, and
reducing airway hyperresponsiveness and asthma exacer-
bation rates (1,2). Their important role in the management
of asthma is reflected in current national and international
asthma management guidelines which recommend early
intervention with inhaled corticosteroids for the treatment
of patients with persistent disease (3–5). For those patientsReceived 22 November 1999 and accepted in revised form 2 May
2000.
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treatment options include increasing the corticosteroid
dose or the addition of a long-acting b2-agonist (3–5).
Several studies published in the last few years support the
combined use of long-acting b2-agonists and an inhaled
corticosteroid for the treatment of asthma (6–11). Indeed,
these studies have shown that adding salmeterol to inhaled
corticosteroid therapy produces greater improvements in
lung function and symptom control than at least doubling
the patients’ existing corticosteroid dose. Furthermore,
these benefits are not associated with an overall reduction
in asthma control as measured by a low incidence of asthma
exacerbations (12).
Based on the complementary mechanisms of action of
salmeterol and fluticasone propionate (13,14), and the
desire to simplify asthma therapy, these agents have
recently been combined in a convenient single, multi-dose,
dry powder DiskusTM inhaler (SeretideTM, AdvairTM,# 2000 HARCOURT PUBLISHERS LTD
716 C. JENKINS ET AL.VianiTM). We describe here the results of the first study to
compare the ecacy and tolerability of this salmeterol/
fluticasone propionate combination (SFC 50/250 mg twice
daily) with a three-fold higher microgram dose (3:1 ratio) of
inhaled corticosteroid (budesonide 1600mg day71) in pa-
tients with moderate to severe persistent asthma remaining
symptomatic on a moderate to high corticosteroid dose
(800–1200 mg day71. This is also the first study to compare
treatment with a combination of a long-acting b2-agonist
and inhaled corticosteroid with another inhaled corticos-
teroid alone administered via a dierent inhaler. The
ecacy parameters measured in the study, i.e. lung function
and symptom control, reflect the goals of current asthma
management guidelines (4) and provide a useful measure of
the overall eectiveness of this combination. The treatment
options compared in this study reflect a clinically important
step in the decision pathway when clinicians are choosing
between increasing the corticosteroid dose or adding in a
long-acting b2-agonist for patients with asthma whose
symptoms remain uncontrolled on their existing dose of
corticosteroid. By using SFC 50/250 mg, these options can
be implemented without increasing the complexity of the
treatment regimen.
Methods
PATIENTS
Patients aged  12 years with a documented history of
reversible airways obstruction receiving inhaled corticoster-
oids (budesonide or beclomethasone dipropionate 800–
1200 mg day71 or fluticasone propionate 400–600 mg day71)
for  4 weeks before the 2-week run-in period were eligible
for study entry. Patients were randomized to study
treatment if during the run-in period they had a pre-
bronchodilator forced expiratory volume in 1 sec (FEV1) or
peak expiratory flow (PEF)  50% and  85% of the
predicted normal value, a  15% increase in FEV1 or mean
morning PEF  85% of maximum achievable after inhala-
tion of a short-acting b2-agonist; used salbutamol (Vento-
linTM) more than twice a day or had a total daytime
plus night-time symptom score  2 (defined as symptoms
at least twice during the day or symptoms causing the
patient to awake at least twice during the night) on  4 of 7
days.
Patients were excluded if in the 4 weeks before the run-in
period they had had an acute exacerbation requiring
hospitalization, had received oral, parenteral or depot
corticosteroids, or had had a lower respiratory tract
infection or change in asthma medication. Other exclusion
criteria included treatment with a long-acting b2-agonist or
slow-release bronchodilator in the 2 weeks before the
run-in period and a smoking history of  10 pack-years.
Pregnant or lactating females were also excluded from
study entry.
Local ethics committee approval was obtained at each
study centre and all patients provided written informed
consent. The study was conducted in accordance with
Good Clinical Practice and the Declaration of Helsinki.STUDY DESIGN
This multinational study was conducted in 44 centres
according to a randomized, double-blind, double-dummy,
parallel-group design. At the beginning of the 2-week run-
in period, all asthma medications were withdrawn except
the patients’ usual inhaled corticosteroid; and salbutamol
was provided for symptomatic relief as required. Patients
were randomized at the end of the run-in period to receive
either SFC (salmeterol 50 mg plus fluticasone propionate
250mg) by DiskusTM plus placebo by TurbuhalerTM (Astra
Zeneca, Lund, Sweden) (breath actuated dry powder
inhaler) twice daily, or budesonide 800 mg by TurbuhalerTM
plus placebo by DiskusTM twice daily for 24 weeks.
Throughout the treatment period, the patients’ usual
inhaled corticosteroid therapy was withdrawn and rescue
salbutamol was provided to be used when required.
ASSESSMENTS
Throughout the study patients kept a daily diary card
record of their morning and evening PEF (best of three
measurements); daytime symptoms using a scale of 0 (no
symptoms) to 5 (symptoms so severe that the patient could
not work or perform normal daily activities); night-time
symptoms using a scale of 0 (no symptoms) to 4 (unable to
sleep at all because of asthma symptoms); and use of rescue
salbutamol during the day and night. Patients were asked to
measure their PEF using a mini-Wright peak flow meter
before taking their study medication or salbutamol. Clinic
FEV1 (highest of three measurements) was recorded before
patients received their study medication or salbutamol
during the run-in period and at weeks 4, 12 and 24 of
treatment.
The investigator recorded the occurrence and severity
of all exacerbations in the clinical record form. A
severe exacerbation of asthma was defined as a deteriora-
tion in asthma requiring emergency hospital treat-
ment. Exacerbations were defined as moderate if
they required administration of additional inhaled
corticosteroids, bronchodilators and/or oral corticoster-
oids. A mild exacerbation was defined as a deterioration
in asthma requiring an increase in the use of relief
medication which the physician considered to be clinically
relevant.
All adverse events were recorded by the investigator
irrespective of their likely causality. A serious adverse event
was defined as any event that was fatal, life-threatening,
disabling, or which required or prolonged hospitalization.
Oropharyngeal examinations were performed before start-
ing study treatment and after 4, 12 and 24 weeks of
treatment; a swab was taken for culture if there was
evidence of candidal infection.
STATISTICAL ANALYSIS
All ecacy and safety analyses were performed on the
intent-to-treat population. The primary ecacy measure
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deviation of 40 lmin71 and the requirement for 90%
power, it was calculated that data for 300 evaluable
patients would be required to demonstrate a dierence of
15 lmin71 with 95% confidence.
Comparison between the treatment groups for morning
PEF over weeks 1 to 24 was made using analysis of
covariance (ANCOVA) allowing for eects due to sex, age,
country, baseline (mean morning PEF during the second
week of run-in) and treatment. All ecacy analyses were
conducted using two-sided tests and symmetric 95%
confidence intervals (CI).
The secondary ecacy measures included incidence and
severity of exacerbations, clinic FEV1, morning PEF during
weeks 1–4, 5–8, 9–12 and 13–24 and all other diary card
data over weeks 1–24, 1–4, 5–8, 9–12 and 13–24, namely
evening PEF, use of rescue salbutamol, diurnal variation
and daytime and night-time symptom scores. The analysis
of FEV1 and all other diary card secondary ecacy
measures was performed using ANCOVA, in a similar
way to the analysis of the primary ecacy measure, or by
the Wilcoxon rank sum test, controlling for country, as
appropriate. The proportion of patients with at least one
asthma exacerbation during treatment was analysed using
logistic regression analysis allowing for eects due to
country, age and sex.
The analysis of the day 1 to 7 data for morning PEF
was performed using a repeated measures ANCOVA
allowing for eects due to age, sex and country. The
analysis of the day 1 to 7 data for the percentage of patients
with no daytime symptoms was performed using a logistic
regression analysis allowing for eects due to age, sex and
country.TABLE 1. Patient demography (intent-to-treat population)
Number of patients
Male (n)
Female (n)
Age (mean;range) [years]
Weight (mean; kg)
Height (mean; cm)
Duration of airways disease (n)
0 to 5 1 year
1 to 5 5 years
5 to 5 10 years
 10 years
Corticosteroid therapy prior to randomization (n)
Fluticasone propionate (median daily dose; mg)
Budesonide (median daily dose; mg)
Beclomethasone dipropionate (median daily dose; mg)
FEV1 % predicted (mean; range)
* One patient was receiving both fluticasone propionate and be
FEV1 forced expiratory volume in 1 sec.Results
Three hundred and fifty-three patients were randomized to
treatment; 180 to SFC and 173 to budesonide. After
randomization, 59 patients were withdrawn, 29 in the SFC
group and 30 in the budesonide group. Reasons for
withdrawal included inability to fulfil the entry criteria
(seven patients and four patients in the two groups,
respectively); exacerbation of asthma (six and five patients);
failure to return (five and six patients); adverse events (three
and four patients); lack of ecacy (one and four patients)
and other reasons (seven patients in both groups). The two
treatment groups were well matched for all demographic
details including FEV1 (Table 1).
Mean morning PEF improved in both treatment groups
over the 24 weeks of the study. The primary ecacy
measure, mean morning PEF over the 24 week treatment
period, was higher in patients treated with SFC than in
those treated with budesonide. The adjusted mean morning
PEF values were 406 lmin71 and 380 lmin71 for SFC and
budesonide respectively. There was a statistically significant
treatment dierence between the groups of 25 lmin71 (95%
CI: 15,35: P50?001) (Table 2). Similar results were seen for
mean morning PEF during weeks 1–4, 5–8, 9–12 and 13–24
(Fig. 1) and mean evening PEF during weeks 1–4, 5–8, 9–
12, 13–24 and overall weeks 1–24 (Table 2).
Improvement in mean morning and evening PEF
occurred within the first week of treatment in both groups;
however, the onset of improvement was significantly faster
in the SFC group, with a significant dierence between
treatments recorded as early as day 1. Figure 2 shows the
improvement in mean morning PEF during the first week of
treatment.SFC Budesonide
180 173
90 (50%) 87 (50%)
90 (50%) 86 (50%)
45 (16–75) 48 (14–80)
77 77
170 168
10 (5%) 11 (6%)
34 (19%) 28 (16%)
31 (17%) 28 (16%)
105 (58%) 106 (62%)
47 (500) 38* (500)
82 (800) 86 (800)
51 (1000) 50* (1000)
68 (33–105%) 72 (37–109%)
clomethasone dipropionate before entry into the study.
TABLE 2. Daily diary card peak expiratory flow (PEF) in patients treated with salmeterol/fluticasone propionate combination
therapy (SFC 50/250 mg) or budesonide (800 mg) twice daily for 24 weeks
n SFC
adjusted
mean (+ SE)*
n Budesonide
adjusted mean
(+ SE)*
Dierence
between
groups*{
95 % CI* P-value*
Morning PEF (lmin71)
Weeks 1–4 173 399 (3?14) 165 374 (3?26) 25 17, 34 50?001
Weeks 5–8 165 403 (3?81) 160 382 (3?92) 21 11, 31 50?001
Weeks 9–12 162 407 (4?11) 153 381(4?28) 25 14, 36 50?001
Weeks 13–24 158 410 (4?49) 147 384 (4?69 26 14, 38 50?001
Weeks 1–24 173 406 (3?67) 165 380 (3?81) 25 15, 35 50?001
Evening PEF (lmin71)
Weeks 1–4 173 412 (2?81) 165 395 (2?91) 16 9, 24 50?001
Weeks 5–8 164 415 (3?39) 160 399 (3?47) 16 7, 25 50?001
Weeks 9–12 162 417 (3?56) 153 397 (3?71) 20 11, 30 50?001
Weeks 13–24 158 420 (3?85) 147 401 (4?03) 19 9, 29 50?001
Weeks 1–24 173 416 (3?14) 165 398 (3?25) 18 9, 26 50?001
Diurnal variation in PEF (%){
Weeks 1–4 173 7 (0?27) 165 9 (0?28) 72 73, 71 50?001
Weeks 5–8 164 6 (0?32) 160 8 (0?32) 71 72, 0 0?002
Weeks 9–12 162 6 (0?31) 153 7 (0?33) 71 72, 0 0?002
Weeks 13–24 158 6 (0?36) 147 7 (0?38) 72 73, 71 0?001
Weeks 1–24 173 6 (0?29) 165 8 (0?30) 72 72, 71 50?001
* From ANCOVA, adjusting for sex, age, country and baseline.
{ Dierence between the adjusted means (SFC minus budesonide).
{ Calculated as (PEFmax7PEFmin)6100/PEFmax
CI: Confidence interval: SE: standard error.
718 C. JENKINS ET AL.Mean diurnal variation in PEF improved in both groups
from a baseline value of 10% (both groups) to 6% in the
SFC group and 8% in the budesonide group over the
24-week treatment period. The adjusted mean diurnalFIG. 1. Mean adjusted morning peak expiratory flow
(PEF+SEM) in patients treated with salmeterol/fluticasone
propionate combination therapy (SFC 50/250 mg) or
budesonide (800mg) twice daily for 24 weeks. Values
shown at each time point were adjusted for age, sex,
country and baseline value. & SFC; & budesonide;
*P5 0?001 vs budesonide.variation in PEF was statistically although not clinically
significantly lower in the SFC group than in the
budesonide group at all assessment periods (P 0?003)
(Table 2).
CLINIC FEV1
In both treatment groups, there was an improvement in
percent predicted FEV1 and absolute FEV1 measured in the
clinic after 4 weeks of treatment and this improvement was
maintained throughout the 24-week treatment period.
Patients treated with SFC had significantly greater
percent predicted FEV1 values at week 4 (78 vs. 74%;
treatment dierence 3%; 95% CI:1, 6; P=0?007) and
absolute FEV1 values at week 4 (2?50 vs. 2?36 l; treatment
dierence 0?14 l; 95% CI: 0?06, 0?22; P5 0?001) and week
24 (2?53 vs. 2?44 l; treatment dierence 0?09 l; 95% CI:0,
0?17; P5 0?050). Although SFC treated patients reported
higher percent predicted FEV1 values at weeks 12 and 24
and higher absolute FEV1 values at week 12 the dierence
between treatments did not reach statistical significance.
SYMPTOM SCORES
The percentage of symptom-free days over 24 weeks was
significantly greater in the SFC group than in the
budesonide group (95% CI: 2, 11; P5 0?001) and the
FIG. 2. Mean morning peak expiratory flow (PEF+SD) in
asthma patients during second run-in week (patients
taking only inhaled corticosteroids) and first week of
treatment with either salmeterol/fluticasone propionate
combination therapy (SFC 50/250 mg) or budesonide
(800mg) twice daily. The daily P-values are based on a
repeated measures analysis adjusting for age, sex and
country. *P5 0?05; **P5 0?01; ***P 0?005.
FIG. 3. Percentage of symptom-free and salbutamol-free
days during treatment with salmeterol/fluticasone
propionate combination therapy (SFC 50/250mg) or
budesonide (800mg) twice daily for 24 weeks. & SFC; &
budesonide; *P=0?019; **P=0?005; ***P 0?001 vs.
budesonide.
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groups) to 60% in the SFC group and 34% in the
budesonide group [Fig. 3(a)]. Although the percentage of
symptom-free nights was slightly higher among the SFC
patients, it was high in both groups and the dierence
between treatments did not reach statistical significance
(median percentages weeks 1 to 24: 86% vs. 79%).
Improvements in symptom control were more rapid
during the first week of treatment with SFC than with
budesonide and these dierences were significant on day 1
for both daytime (P 0?029) (Fig. 4) and night-time
symptom scores (P=0?035).
RESCUE MEDICATION USE
Significantly higher percentages of salbutamol-free days
were reported in the SFC group (P 0?001) for all
assessment periods [Fig. 3(b)], and for the percentage of
salbutamol-free nights during weeks 5 to 8, 13 to 24 and
weeks 1 to 24 (P5 0?03). The percentages of salbutamol-
free nights were 90% and 82% during weeks 1 to 24 in the
SFC and budesonide groups, respectively, (P=0?029; 95%
CI: 0,4).
EXACERBATIONS OF ASTHMA
The majority of patients in both treatment groups
experienced no exacerbations of asthma during the 6-month study period. The number and severity of exacer-
bations in both groups were similar (Table 3), suggesting
that overall control of asthma was maintained following the
addition of a long-acting b2-agonist. The incidence of
exacerbations recorded in this study reflects the long
duration of the treatment period, and the severity of
asthma in the population studied. Six patients in the SFC
group and five in the budesonide group experienced three
or more exacerbations. One patient in the SFC group and
two patients in the budesonide group experienced at least
one severe exacerbation.
ADVERSE EVENTS
Both treatment regimens were well tolerated. During the
24-week treatment period, 25 and 31 patients in the SFC
and budesonide groups, respectively, reported adverse
events which in the opinion of the investigators were
related to study treatment. The most common adverse
events considered to be treatment-related by the
FIG. 4. Percentage of asthma patients reporting no
daytime symptoms during the second run-in week
(patients taking only inhaled corticosteroids) and the first
week of treatment with either salmeterol/fluticasone
propionate combination therapy (SFC 50/250 mg) or
budesonide (800mg) twice daily. *P5 0?05; **P5 0?01.
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and oral candidiasis (five patients; 3%) in the SFC group,
and hoarseness (nine patients; 5%) and sore, dry or
irritated throat (seven patients; 4%) in the budesonide
group (Table 4). Six patients experienced one or more
serious adverse events during treatment with SFC (myo-
cardial infarction, atrial fibrillation, paracetamol overdose,
tendon rupture, hand fracture, asthma exacerbation
and prostatitis) and six patients experienced one or
more serious adverse events during treatment with budeso-
nide (brain stem infarct, tachycardia, vitreous haemor-
rhage, asthma exacerbation, endometriosis, knee joint
disorder and pneumonia). None of these serious adverse
events were judged by the investigators to be treatment-
related.TABLE 3. Severity of asthma excerberations in patients treated w
(SFC 50/250mg) or budesonide (800 mg) twice daily for 24 week
SFC (n=180)*
n (%)
Patients with no exacerbations 126 (70)
Patients with 1 exacerbation
Mild 36 (20)
Moderate 28 (16)
Severe 1 (0?6)
* There was no statistically significant dierence between treatmDiscussion
This study demonstrates that patients with moderate to
severe asthma remaining symptomatic on maintenance
therapy with budesonide 800 to 1200 mg day71 (or equiva-
lent) derive greater benefit from switching to SFC 50/250mg
twice daily (salmeterol 50mg and fluticasone propionate
250mg given in combination) via a single dry powder
inhaler (DiskusTM) than from a three-fold greater dose of
inhaled corticosteroid (budesonide 800mg twice daily).
SFC was found to be superior to budesonide at a 1:3 mg
steroid dose ratio in this study in terms of an improvement
in the primary ecacy measure, morning PEF. SFC was
also significantly superior to budesonide in terms of
daytime symptom control and use of rescue salbutamol.
The percentage of symptom-free nights was high in both
groups, with a non-significant trend in favour of SFC.
The superior ecacy of SFC demonstrated in this study
confirms the findings of earlier studies comparing the
combination of salmeterol and beclomethasone dipropio-
nate or fluticasone propionate with increasing the inhaled
corticosteroid dose (6–9,11). However, this is the first
clinical trial at a 1:3 inhaled corticosteroid dose ratio,
highlighting that SFC has equivalent or superior ecacy
compared with budesonide despite the lower microgram
corticosteroid dose. The results also emphasize the poten-
tial steroid-sparing eect of salmeterol. These findings are
consistent with current national and international asthma
management guidelines which recommend using the lowest
possible corticosteroid dose needed to maintain control of
asthma (3,4). The additional clinical benefit of SFC
compared with a higher dose of inhaled corticosteroid
may be attributable to the complementary mechanisms of
action of these two agents (13,14). The anti-inflammatory
eect of inhaled corticosteroids and the bronchodilator
eect of long-acting b2-agonists are recognized to be
complementary in the treatment of asthma. In addition,
there is evidence to suggest that salmeterol enhances the
activity of fluticasone propionate, through interaction with
the glucocorticoid receptor (15). Furthermore, it is known
that corticosteroids induce transcription of the b2-adreno-
ceptor gene, so increasing the synthesis of b2-receptor
protein (16). At the cellular level, evidence of complementaryith salmeterol/fluticasone propionate combination therapy
s
Budesonide* (n=173)
n (%)
95% CI P-value
121 (70)
27 (16) 0?74, 2?25 0?382
29 (17) 0?54, 1?73 0?913
2 (1)
ents.
TABLE 4. Number of patients (%) experiencing adverse
events (AEs) during treatment with salmeterol/fluticasone
propionate combination therapy (SFC 50/250mg) or
budesonide (800 mg) twice daily for 24 weeks that were
considered to be treatment-related in the opinion of the
investigators: adverse events experienced by 2% of
patients in at least one treatment group are presented
Description of AE Number of patients (%)
SFC
(n=180)
Budesonide
(n=173)
Hoarseness 6 (3%) 9 (5%)
Sore, dry or irritated throat 3 (2%) 7 (4%)
Asthma exacerbation 3 (2%) 4 (2%)
Oral candidiasis 5 (3%) 1 (51%)
Candidiasis (unspecified site) 1 (51%) 5 (3%)
Laryngitis/pharyngitis 2 (1%) 3 (2%)
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long-acting b2-agonists has been observed; this includes
eects on T-cell proliferation (17) and eosinophil apoptosis
(18).
A meta-analysis of seven comparative studies indicates
that fluticasone propionate has a clinical potency approxi-
mately twice that of budesonide, with an improved
therapeutic index (ecacy: safety ratio) (19). The implica-
tions of these findings are that the benefits of SFC over
budesonide may have been due not just to the addition of a
long-acting b2-agonist but also to the greater topical
ecacy of fluticasone propionate relative to budesonide.
The results of our study suggest that the therapeutic ratio
may be even higher than 2:1 when fluticasone propionate is
used in combination with salmeterol as SFC. Johansson et
al. (20) reported a similar finding after comparing a lower
strength of fluticasone propionate in SFC (50/100 mg twice
daily) with four times the microgram dose of budesonide
(400mg twice daily).
During the run-in period in our study, patients continued
to take the same dose of inhaled corticosteroid as before
entering the study, the median dose being 400 mg of
beclomethasone dipropionate or equivalent twice daily.
Assuming a 2:1 potency ratio of fluticasone propionate to
beclomethasone dipropionate or equivalent (19), compar-
ison of the median inhaled corticosteroid dose during the
run-in period with the median corticosteroid dose received
during the treatment period showed that the inhaled
corticosteroid dosage was increased in all patients in the
budesonide group (doubling in 49% of patients and
increasing by 60% in the remainder). In contrast, in the
SFC group the corticosteroid dosage remained unchanged
(54%) or increased by just 25% (46% of patients). This
study confirms the clinical ecacy and positioning in
guidelines of the combination of inhaled corticosteroids
and long-acting b2-agonists as an alternative to increasingthe inhaled corticosteroid dose in many patients who are
symptomatic on their existing corticosteroid therapy.
In this study, improvements in lung function and
symptom control were significant from the first day of
treatment with SFC. This rapid onset of eect may
facilitate adherence with inhaled corticosteroid therapy.
Furthermore, the simplicity and convenience of therapy
with the two drugs delivered via a single breath-actuated
inhaler may also lead to improved adherence.
It has been suggested that regular use of a short-acting
b2-agonist may worsen asthma control and mask any
deterioration in the underlying inflammation leading to an
increase in the rate and severity of asthma exacerbations
(21). As a consequence there has been concern that
maintenance therapy with a long-acting b2-agonist could
result in a deterioration in asthma control. Furthermore, in
the present study the ability of the relatively low steroid
dose used in the SFC group to control inflammation in
these moderate to severe asthmatics might be questioned.
However, our results indicate that control of inflammation
was in fact similar in both treatment groups. For example,
the incidence and severity of asthma exacerbations was
comparable in the SFC and budesonide groups. A number
of other clinical studies comparing inhaled corticosteroids
plus long-acting b2-agonists with inhaled corticosteroid
therapy alone have shown similar results (12,22,23). In the
FACET (Formoterol and Corticosteroids Establishing
Therapy) study the addition of formoterol 24mg day71 to
budesonide 800 mg day71 reduced the rate of severe and
mild exacerbations by 63% and 62%, respectively (12).
Furthermore, the exacerbations experienced by patients
receiving formoterol did not dier in severity or in their
response to treatment compared with those experienced by
patients receiving budesonide alone (24). Ind et al. (22) also
reported similar findings in a study comparing concurrent
therapy with salmeterol (50 mg twice daily) and fluticasone
propionate (250 mg twice daily), with fluticasone propionate
alone (500 or 1000 mg day71). No significant dierence in
exacerbation rate was reported in another study comparing
the eect of adding salmeterol 100mg day71 or placebo to
patients’ existing inhaled corticosteroid therapy (beclo-
methasone dipropionate or budesonide) (23). In addition
the diurnal variation in PEF (which has been associated
with a deterioration in asthma control) (25,26) was
statistically lower (although clinically similar) in the
SFC group throughout our study indicating that SFC
controls these clinical markers of inflammation at least as
eectively as budesonide, at a lower microgram dose of
corticosteroid.
This study has shown that salmeterol 100 mg day71 and
fluticasone propionate 500mg day71 combined in a single
DiskusTM inhaler is more eective in the treatment of
moderate to severe asthma than a three-fold greater
microgram dose of budesonide (800 mg twice daily),
in terms of improvement in lung function and symptom
control. These results support the complementary
mechanisms of action of long-acting b2-agonists and
inhaled corticosteroids and emphasize the value of combi-
nation therapy with these agents in the management of
asthma.
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